Trinity Delta view: Updated SGC data in 30-patients confirm that the efficacy and safety signals seen in Phase Ia are consistent and meaningful. Maturing data from the Phase 1b cohort will guide design of the Phase II/III registration study in SGC. Whilst clearly important, we view the real significance of this encouraging data as providing the proof-of-concept for Avacta’s FAP-targeted pipeline. Although faridoxorubicin has a clear clinical, and commercial, role, the greater value of Avacta’s pre|CISION platform lies in the next-generation programmes that are being progressed through preclinical development. The ability to selectively activate highly potent drugs in the TME should lead to a valuable pipeline of novel, and highly relevant, targeted therapeutics.
